Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Cholangiocarcinoma 2Solid Tumor, Miscellaneous 1Recurrence 1Pancreatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Liposarcoma 1Leukemia, Myeloid, Acute 1Hematologic Neoplasms 1Gastrointestinal Stromal Tumors 1Gastrointestinal Neoplasms 1

Interventions

Cyclophosphamide 21venetoclax 18pembrolizumab 16Dexamethasone 16fludarabine 14Cytarabine 13Gemcitabine 9pomalidomide 8Rituximab 8Carboplatin 8Azacitidine 8glofitamab 7fludarabine phosphate 7Lenalidomide 7Immunotherapy, Adoptive 7selinexor 6Paclitaxel 6Injections 6Granulocyte Colony-Stimulating Factor 6Cisplatin 6daratumumab 5Temozolomide 5Oxaliplatin 5Bevacizumab 5zanubrutinib 4ruxolitinib 4Surgical Procedures, Operative 4Nivolumab 4Drug Therapy 4Decitabine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Recurrence × pemigatinib × Clear all
NCT06300528 2025-12-03

Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas

University of Utah

Phase 2 Recruiting
27 enrolled
Lymphoid

Recurrence, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡